
    
      Cinepazide was firstly approved in France in 1974, and the formulations are injection and
      tablet. Products containing cinepazide have been withdrawn in 1990s by the manufacturers
      because of lacking of demonstrated efficacy and the risk of agranulocytosis in some European
      countries, such as France, Spain, Italy. In some Aisa countries, it has not been
      re-registered in Japan in 2000s, and the injection is still used in China and Korea. In
      china, Cinepazide Maleate Injection was approved by China Food and Drug Administration(CFDA)
      in 2002, and widely used in cerebrovascular disease. The safety of the Cinepazide, especially
      the adverse drug reactions in the blood system, has not benn fully evaluated in Chinese
      population. In this study, clinical pharmacists in selected hospitals will record the
      clinical use and the adverse drug reactions/ adverse drug events of this injection. This real
      world study for Cinepazide Maleate Injection with 18000 patients will be conducted from Sep.
      2012 to June. 2014.
    
  